U.S. flag An official website of the United States government
  1. Home
  2. Drug Databases
  3. Orange Book Home

Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations

Home | Back to Product Details

Additional Information about Patents

  • Patent information is published on or after the submission date as defined in 21 CFR 314.53(d)(5).
  • Patent listings published prior to August 18, 2003, only identify method-of-use claims. The listed patents may include drug substance and/or drug product claims that are not indicated in the listing.
  • As of December 5, 2016, an NDA holder submitting information on a patent that claims both the drug substance and the drug product (and is eligible for listing on either basis) is required only to specify that it claims either the drug substance or the drug product. Orange Book users should not rely on an Orange Book patent listing, regardless of when first published, to determine the range of patent claims that may be asserted by an NDA holder or patent owner.

Patent and Exclusivity for: N204824

Product 006
METHOTREXATE (OTREXUP) SOLUTION 12.5MG/0.4ML (12.5MG/0.4ML)

Patent Data

Product No Patent No Patent Expiration Drug Substance Drug Product Patent Use Code Delist Requested Submission Date
006 8021335 10/04/2026 DP 06/01/2016
006 8480631 03/19/2030 DP U-1442 06/01/2016
006 8562564 01/24/2026 DP 06/01/2016
006 8579865 03/19/2030 DP U-1442 06/01/2016
006 8814834 05/27/2031 DP 08/14/2020
006 8945063 03/19/2030 DP U-1442 06/01/2016
006 9421333 03/19/2030 DP U-1442 09/21/2016
006 9533102 01/24/2026 DP 02/02/2017
006 9629959 01/24/2026 DP 05/25/2017
006 9867949 03/10/2029 DP 08/14/2020
006 10709844 03/10/2029 DP 08/14/2020
006 11446441 01/24/2026 DP 10/19/2022
006 11497753 03/19/2030 DP 12/13/2022
006 11684723 03/10/2029 DP 07/19/2023

Exclusivity Data

Product No Exclusivity Code Exclusivity Expiration

 

 


View a list of all patent use codes
View a list of all exclusivity codes

Back to Top